The state-of-the-art in chemoprevention of skin cancer

European Journal of Cancer

Volumn 36, Issue 10, 2000, Pages 1292-1297

  Stratton, S P ^a   Dorr, R T ^a   Alberts, D S ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Chemoprevention; Clinical trials; Skin neoplasms; Ultraviolet rays

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CAROTENE; BIOLOGICAL MARKER; EFLORNITHINE; EPIGALLOCATECHIN GALLATE; ISOTRETINOIN; LIMONENE; ORNITHINE DECARBOXYLASE INHIBITOR; PERILLYL ALCOHOL; PLACEBO; RAS PROTEIN; RETINOID; RETINOL; SALICYLIC ACID; SELENIUM; SUNSCREEN; TRANSCRIPTION FACTOR AP 1;

ANIMAL MODEL; CANCER INCIDENCE; CANCER PREVENTION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS; TEA; TRANSGENIC MOUSE; ULTRAVIOLET RADIATION;

ANIMALS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE III; EFLORNITHINE; HUMANS; MELANOMA; MICE; RANDOMIZED CONTROLLED TRIALS; SELENIUM; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSCRIPTION FACTOR AP-1; ULTRAVIOLET RAYS; VITAMIN A;

EID: 0034042963     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00108-8     Document Type: Conference Paper

References (51)

1. Shouse TA, Day CL. Malignant melanoma. In Weiss GR, ed. Clinical Oncology. Norwalk, Connecticut, Appleton & Lange, 1993, 247-256.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997, 47, 5-27.
3. Grossman D, Leffell DJ. The molecular basis of nonmelanoma skin cancer: new understanding. Arch Dermatol 1997, 133, 1263-1270.
4. Fears TR, Scotto J. Estimating increases in skin cancer morbidity due to increases in ultraviolet radiation exposure. Cancer Invest 1983, 1, 119-126.
5. Lloyd SA. Stratospheric ozone depletion. Lancet 1993, 342, 1156-1158.
6. Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992, 26, 1-26.
7. Moller RF, Reymann F, Hou-Jensen K. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol 1979, 115, 703-705.
8. Demetrius RW, Randle HW. High-risk nonmelanoma skin cancers. Dermatol Surg 1998, 24, 1272-1292.
9. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000, 50, 7-33.
10. Miller SJ. Biology of basal cell carcinoma (Part I). J Am Acad Dermatol 1991, 24, 1-13.
11. Randle HW. Basal cell carcinoma. Identification and treatment of the high-risk patient. Dermatol Surg 1996, 22, 255-261.
12. Hall III, Miller DR, Rogers JD, Bewerse B. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999, 40, 35-42.
13. Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999, 340, 1341-1348.
14. Morton DS, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996, 46, 217-224.
15. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18, 158.
16. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology (Huntingl) 1995, 9, 1149-1158.
17. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ('actinic keratosis'). J Am Acad Dermatol 2000, 42, 11-17.
18. Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997, 6, 949-956.
19. Einspahr JG, Alberts DS, Warneke JA, et al. Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis. Neoplasia 1999, 1, 468-475.
20. Einspahr J, Alberts DS, Aickin M, et al. Expression of p53 protein in actinic keratosis, adjacent, normal-appearing, and nonsun-exposed human skin. Cancer Epidemiol Biomarkers Prev 1997, 6, 583-587.
21. Einspahr J, Alberts DS, Aickin M, et al. Evaluation of proliferating cell nuclear antigen as a surrogate end point biomarker in actinic keratosis and adjacent, normal-appearing, and nonsun-exposed human skin samples. Cancer Epidemiol Biomarkers Prev 1996, 5, 343-348.
22. Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 1994, 85, 23-29.
23. Greenberg ER, Baron JA, Stukel TA, et al. A clinical trial of beta-carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 1990, 323, 789-795.
24. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. J Am Med Assoc 1996, 276, 1957-1963.
25. Marks R. An overview of skin cancers. Incidence and causation. Cancer 1995, 75, 607-612.
26. Chen W, Borchers AH, Dong Z, Powell MB, Bowden GT. UVB irradiation-induced activator protein-1 activation correlates with increased c-fos gene expression in a human keratinocyte cell line. J Biol Chem 1998, 273, 32176-32181.
27. Yang CS, Wang ZY. Tea and Cancer. J Natl Cancer Inst 1993, 85, 1038-1049.
28. Mukhtar H, Katiyar SK, Agarwal R. Green tea and skin-anticarcinogenic effects. J Invest Dermatol 1994, 102, 3-7.
29. Okuda T, Mori K, Hayatsu H. Inhibitory effect of tannins on direct-acting mutagens. Chem Pharm Bull 1984, 32, 3755-3758.
30. Salah N, Miller NJ, Paganga G, Tijburg L, Bolwell GP, Rice-Evans C. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch Biochem Biophys 1995, 322, 339-346.
31. Valcic S, Timmermann BN, Alberts DS, et al. Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs 1996, 7, 461-468.
32. Gensler HL, Timmermann BN, Valcic S, et al. Prevention of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green tea. Nutr Cancer 1996, 26, 325-335.
33. Barthelman M, Bair WB3, Stickland KK, et al. (-)-Epigallo-catechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity. Carcinogenesis 1998, 19, 2201-2204.
34. Chen W, Barthelman M, Lin L, Bowden GT. EGCG inhibits UVB induced AP-1 activation and c-fos gene expression in a human keratinocyte cell line. Proc Am Assoc Cancer Res 1998, 39, 391.
35. Chen W, Bowden GT. Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fos gene expression in human keratinocytes. Oncogens 1999, 18, 7469-7476.
36. Chen W, Dong Z, Valcic S, Timmermann BN, Bowden GT. Inhibition of ultraviolet B-induced c-fos gene expression and p38 mitogen-activated protein kinase activation by (-)-epigallocatechin gallate in a human keratinocyte cell line. Mol Carcinog 1999, 24, 79-84.
37. Barthelman M, Chen W, Gensler HL, Huang C, Dong Z, Bowden GT. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res 1998, 58, 711-716.
38. Crowell PL, Ren Z, Lin S, Vedejs E, Gould MN. Structureactivity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 1994, 47, 1405-1415.
39. Huang C, Ma WY, Hanenberger D, Cleary MP, Bowden GT, Dong Z. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem 1997, 272, 26325-26331.
40. Powell MB, Hyman P, Bell OD, et al. Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. Mol Carcinog 1995, 12, 82-90.
41. Kramer TR, Powell MB, Wilson MM, Salvatore J, Grossniklaus HE. Pigmented uveal tumours in a transgenic mouse model. Br J Ophthalmol 1998, 82, 953-960.
42. Broome Powell M, Cause PR, Hyman P, et al. Induction of melanoma in TPras transgenic mice. Carcinogenesis 1999, 20, 1747-1753.
43. Cause PR, Lluria-Prevatt M, Keith WN, et al. Chromosomal and genetic alterations of 7,12-dimethylbenz[a]anthracene-induced melanoma from TP-ras transgenic mice. Mol Carcinog 1997, 20, 78-87.
44. Halaban R, Fan B, Ahn J, Funasaka Y, Gitay-Goren H, Neufeld G. Growth factors, receptor kinases, and protein tyrosine phosphatases in normal and malignant melanocytes. J Immunother 1992, 12, 154-161.
45. Lluria-Prevatt M, Taylor M, Liebler DC, Powell MB. In vitro and In vivo models of UV-induced photodamage and melanoma development. Proc Am Assoc Cancer Res 1999, 40, 502.
46. Hong WK, Lippman SM. Cancer chemoprevention. J Natl Cancer Inst Monogr 1995, 49-53.
47. Levine N, Moon TE, Cartmel B, et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997, 6, 957-961.
48. Pegg AE, Shantz LM, Coleman CS. Ornithine decarboxylase as a target for chemoprevention. J Cell Biochem Suppl 1995, 22, 132-138.
49. Francz PI, Conrad J, Biesalski HK. Modulation of UVA-induced lipid peroxidation and suppression of UVB-induced ornithine decarboxylase response by all-trans-retinoic acid in human skin fibroblasts in vitro. Biol Chem 1998, 379, 1263-1269.
50. Nelson MA, Porterfield BW, Jacobs ET, Clark LC. Selenium and prostate cancer prevention. Semin Ural Oncol 1999, 17, 91-96.
51. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst 1998, 90, 1514-1528.